Comparison of suitable naïve versus pretreated DMO patients

Video
Conference|EURETINA

Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.


Dr Javier Zarranz-Ventura, a vitreoretinal consultant at
Institut Clínic de Oftalmologia (ICOF), Hospital Clínic de Barcelona andInstitut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS), discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.

See more EURETINA coverage

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
Related Content
The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 5th 2025
Article

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person types on a computer. An AI brain is over the screen. Concept image for artificial intelligence, therapy planning assistant system, TPS, Europe, CE mark. Image credit: ©New Africa – stock.adobe.com

EU issues CE mark for AI therapy planning assistant from deepeye Medical

Jordana Joy
June 2nd 2025
Article

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An image of two containers of vitamin B supplements. Concept image for choline, b6, b9 and b12 vitamins in neuroprotection for glaucoma. ©itsflowingtothesoul – stock.adobe.com

Research indicates B vitamins and choline provide neuroprotection against glaucoma

Lynda Charters
May 26th 2025
Article

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

A single-shot, 130-degree OCTA image of the retina captured using DREAM OCT. Image courtesy of Intalight

EMA issues CE mark for DREAM OCT (Intalight)

Jordana Joy
May 22nd 2025
Article

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

© 2025 MJH Life Sciences

All rights reserved.